PDUFA V Discussions To Begin With April 12 Meeting
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA asks participants to focus on user fee processes and funding, not policy.
You may also be interested in...
Earlier Attention To REMS Could Keep Drug Approvals On Schedule, Industry Says At FDA Meeting
BIO member survey finds 77 percent of firms with REMS report that risk discussions prolonged product reviews.
Earlier Attention To REMS Could Keep Drug Approvals On Schedule, Industry Says At FDA Meeting
BIO member survey finds 77 percent of firms with REMS report that risk discussions prolonged product reviews.
FDA's Appropriations Outlook: More Purse, Emphasis On The Strings
Giving FDA more resources has vocal support on Capitol Hill, but so does changing the way the agency operates.